Helsinn Group, a Switzerland-based cancer company, has set up its second corporate venture capital fund targeting €100m ($120m).
Its 3B Future Health Fund II is incorporated in Luxembourg where the anchor investors will be the Helsinn Group and the Braglia family, which founded and run Helsinn.
The fund will invest in US and European-based, early-stage entrepreneurs in oncology and rare diseases therapeutics and follows the 3B Future Health Fund I, formerly known as Helsinn Investment Fund.
Riccardo Braglia, Helsinn Group vice-chairman and CEO, and Francesco Giavatto, Francesco Granata and Roberto De Ponti are its general partners.
Braglia said: “We are excited by the prospects of the healthcare sector and have high aspirations for this fund.”
